Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir.
Pluronic® F127
acyclovir
controlled release
cyclodextrins mixture
polypseudorotaxanes
solubilization
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
27 Mar 2020
27 Mar 2020
Historique:
received:
28
02
2020
revised:
20
03
2020
accepted:
23
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
Acyclovir (ACV) is one of the most used antiviral drugs for the treatment of herpes simplex virus infections and other relevant mucosal infections caused by viruses. Nevertheless, the low water solubility of ACV limits both its bioavailability and antiviral performance. The combination of block copolymer micelles and cyclodextrins (CDs) may result in polypseudorotaxanes with tunable drug solubilizing and gelling properties. However, the simultaneous addition of various CDs has barely been investigated yet. The aim of this work was to design and characterize ternary combinations of Pluronic® F127 (PF127), αCD and βCD in terms of polypseudorotaxane formation, rheological behavior, and ACV solubilization ability and controlled release. The formation of polypseudorotaxanes between PF127 and the CDs was confirmed by FT-IR spectroscopy, X-ray diffraction, and NMR spectroscopy. The effects of αCD/βCD concentration range (0-7%
Identifiants
pubmed: 32230723
pii: nano10040613
doi: 10.3390/nano10040613
pmc: PMC7221812
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : 20157WZM8A
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : SAF2017-83118-R
Organisme : Agencia Estatal de Investigación
ID : n
Organisme : Xunta de Galicia
ID : ED431C 2016/008
Organisme : Xunta de Galicia
ID : AEMAT ED431E 2018/08
Organisme : European Regional Development Fund
ID : FEDER
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Int J Pharm. 1999 Mar 25;180(1):91-103
pubmed: 10089296
Eur J Pharm Biopharm. 2014 Aug;87(3):579-88
pubmed: 24769064
J Control Release. 2004 Feb 10;94(2-3):351-63
pubmed: 14744486
J Am Chem Soc. 2003 Feb 19;125(7):1788-95
pubmed: 12580604
J Control Release. 2008 May 8;127(3):189-207
pubmed: 18321604
J Pharm Sci. 1962 Aug;51:802-4
pubmed: 13907274
Amino Acids. 2015 Oct;47(10):2215-27
pubmed: 25985927
Wound Repair Regen. 2019 Mar;27(2):183-189
pubmed: 30520197
Chem Rev. 2006 Mar;106(3):782-817
pubmed: 16522009
J Pharm Sci. 2008 Dec;97(12):5061-73
pubmed: 18425814
Pharm Res. 2006 Dec;23(12):2709-28
pubmed: 17096184
Angew Chem Int Ed Engl. 2005 Jan 14;44(4):520-54
pubmed: 15625667
Int J Pharm. 2015 Jul 25;490(1-2):1-8
pubmed: 25980731
Org Biomol Chem. 2010 Dec 7;8(23):5423-30
pubmed: 20859603
J Control Release. 2008 Feb 18;126(1):17-25
pubmed: 18079013
J Phys Chem B. 2009 Mar 5;113(9):2773-82
pubmed: 19708112
Commun Agric Appl Biol Sci. 2007;72(2):137-41
pubmed: 18399434
J Pharm Sci. 2012 Sep;101(9):3019-32
pubmed: 22334484
J Biomed Mater Res. 1972 Nov;6(6):571-82
pubmed: 4642986
Polymers (Basel). 2016 May 17;8(5):
pubmed: 30979290
Drugs. 1994 Jan;47(1):153-205
pubmed: 7510619
Eur J Pharm Biopharm. 2012 Jan;80(1):103-12
pubmed: 22005155
Drug Dev Ind Pharm. 2016 Sep;42(9):1446-54
pubmed: 26765786
Drug Deliv. 2014 Nov;21(7):540-7
pubmed: 24215288
J Phys Chem B. 2011 Mar 31;115(12):2759-64
pubmed: 21384834
Nanomaterials (Basel). 2019 May 15;9(5):
pubmed: 31096569
Clin Pharmacokinet. 2014 Jul;53(7):581-610
pubmed: 24871768
J Infect. 1983 May;6(1 Suppl):3-9
pubmed: 6350472
Pharmaceutics. 2018 Sep 12;10(3):
pubmed: 30213143
ACS Appl Mater Interfaces. 2015 Nov 4;7(43):23831-6
pubmed: 26502827
Int J Pharm. 2018 Dec 1;552(1-2):39-47
pubmed: 30253214
Int J Pharm. 2015 Nov 10;495(1):463-473
pubmed: 26362078
Eur J Pharm Sci. 2018 May 16;121:200-209
pubmed: 29777854
Molecules. 2012 May 21;17(5):6056-70
pubmed: 22614860
Acta Pharm. 2016 Mar;66(1):119-28
pubmed: 26959548
Int J Mol Sci. 2013 Jun 25;14(7):13022-41
pubmed: 23799358
Bioconjug Chem. 2018 Feb 21;29(2):503-516
pubmed: 29357235
Curr Top Med Chem. 2014;14(4):494-509
pubmed: 24354670
J Pharm Sci. 2016 Sep;105(9):2855-2863
pubmed: 27103010